Inclusion Criteria:

- evidence of progressive disease after standard first line treatment of mesothelioma;
OR patient has refused standard first line treatment of mesothelioma

- evaluable disease

- No radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic
agents within 14 days prior to infusion of the IFN-α vector

- Must have a pleural space involved with tumor accessible for pleural catheter
insertion

- FEV1> 1 liter or 40% of predicted value

- Must have an anti-adenoviral neutralizing antibody titer equal to or less than
1:1000. This will be measured by the Penn Vector Core

Exclusion Criteria:

- Presence of HIV or Hepatitis B infection

- Use of concurrent systemic steroids, immunosuppressives, or any other medications
that can directly or indirectly suppress the immune system

- Presence of any other life-threatening illness, such as unstable angina, severe
oxygen dependence, significant chronic obstructive pulmonary disease (COPD), end
stage liver or renal disease

- Presence of untreated brain metastases

- Prior bone marrow or stem cell transplants